Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

49.05 -0.16 (-0.32%)

Streaming Delayed Price Updated: 2:03 PM EST, Dec 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

83 84 Next >

Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave

March 26, 2024

Via AB Newswire

Topics Intellectual Property

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

March 25, 2024

From Bristol Myers Squibb

Via Business Wire

Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum

March 22, 2024

Via AB Newswire

Topics Artificial Intelligence Intellectual Property

Check Out What Whales Are Doing With BMY ↗

March 19, 2024

Via Benzinga

Why NYSE:BMY is a Top Pick for Dividend Investors. ↗

March 12, 2024

Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) a Good Fit for Dividend Investing?

Via Chartmill

Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb ↗

March 11, 2024

Via Benzinga

Bristol-Myers Squibb's Options Frenzy: What You Need to Know ↗

March 04, 2024

Via Benzinga

Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer ↗

March 21, 2024

The European Commission approved Bristol Myers Squibb's Abecma for relapsed/refractory multiple myeloma, making it the first CAR T cell therapy endorsed in the EU for earlier treatment lines.

Via Benzinga

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

March 20, 2024

From Bristol Myers Squibb

Via Business Wire

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy ↗

March 20, 2024

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...

Via Benzinga

Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma

March 20, 2024

From Bristol Myers Squibb

Via Business Wire

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

March 20, 2024

Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel

Via MarketBeat

AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments ↗

March 19, 2024

AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...

Via Benzinga

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

March 19, 2024

From Bristol Myers Squibb

Via Business Wire

FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer ↗

March 18, 2024

FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...

Via Benzinga

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

March 18, 2024

From Bristol Myers Squibb

Via Business Wire

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

March 15, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy ↗

March 15, 2024

FDA grants accelerated approval to Bristol Myers Squibb's Breyanzi, a CAR T cell therapy for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two prior lines of...

Via Benzinga

What's Going On With Cancer Focused-Geron Stock On Friday? ↗

March 15, 2024

Geron sees lower share price with high volume. FDA committee votes favorably on imetelstat for transfusion-dependent anemia in adult MDS patients. June 16, 2024, set as FDA target action date....

Via Benzinga

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

March 14, 2024

From Bristol Myers Squibb

Via Business Wire

FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers ↗

March 13, 2024

Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...

Via Benzinga

Be A Smart Investor – Don’t Hold On For Dear Life ↗

March 13, 2024

You have to give credit where it’s due. The bulls have been relentless for almost 18 months, but certainly over the past 5 months.

Via Talk Markets

Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024

March 11, 2024

From Bristol Myers Squibb

Via Business Wire

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

March 07, 2024

From Bristol Myers Squibb

Via Business Wire

Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 ↗

March 07, 2024

Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...

Via Benzinga

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

March 06, 2024

From Bristol Myers Squibb

Via Business Wire

Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town ↗

March 06, 2024

Discover must-have stocks for wealth for every investor, from healthcare and communication giants to financial and industrial sectors.

Via InvestorPlace

Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic ↗

March 05, 2024

As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 04, 2024

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

83 84 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.